Pluri Announced That Its CDMO Division Has Signed A Manufacturing Agreement With Remedy Cell Ltd For Cell-derived Cell-free Drug Manufacturing
Portfolio Pulse from Benzinga Newsdesk
Pluri has entered into a manufacturing agreement with Remedy Cell Ltd for the production of cell-derived, cell-free drugs through its CDMO division. This partnership aims to leverage Pluri's manufacturing capabilities to produce innovative drug formulations.
March 14, 2024 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pluri's new manufacturing agreement with Remedy Cell Ltd could enhance its position in the biotech industry by expanding its manufacturing capabilities into innovative cell-derived, cell-free drug production.
The agreement with Remedy Cell Ltd positions Pluri at the forefront of innovative drug manufacturing, potentially leading to increased demand for its CDMO services. This could result in positive investor sentiment and an uptick in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90